The characterization of anti-T-cruzi activity relationships between ferrocenyl, cyrhetrenyl complexes and ROS release
Author
dc.contributor.author
Echeverría, César
Author
dc.contributor.author
Romero, Valentina
Author
dc.contributor.author
Arancibia, Rodrigo
Author
dc.contributor.author
Klahn, Hugo
Author
dc.contributor.author
Montorfano, Ignacio
Author
dc.contributor.author
Armisen Yáñez, Ricardo
Author
dc.contributor.author
Borgna, Vincenzo
Author
dc.contributor.author
Simon, Felipe
Author
dc.contributor.author
Ramírez Tagle, Rodrigo
Admission date
dc.date.accessioned
2016-12-28T20:16:40Z
Available date
dc.date.available
2016-12-28T20:16:40Z
Publication date
dc.date.issued
2016
Cita de ítem
dc.identifier.citation
Biometals (2016) 29:743–749
es_ES
Identifier
dc.identifier.other
10.1007/s10534-016-9953-1
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/142176
Abstract
dc.description.abstract
Trypanosoma cruzi (T. cruzi) is the parasite that causes Chagas disease. Nifurtimox is the most used drug against the T. cruzi, this drug increases intermediaries nitro group, being mainly responsible for the high toxicity component, for this reason it is important to study new organic compounds and thus improve therapeutic strategies against Chagas disease. The electronic effects of ferrocenyl and cyrhetrenyl fragments were investigated by DFT calculation. A close correlation was found between HOMO-LUMO gap of nitro radical NO (2) (-) with the experimental reduction potential found for nitro group and IC50 of two forms the T. cruzi (epimastigote and trypomastigote). The IC50 on human hepatoma cells is higher for both compounds compared to IC50 demonstrated in the two forms the T. cruzi, and additionally show reactive oxygen species release. The information obtained in this paper could generate two new drugs with anti-T. cruzi activity, but additional studies are needed.
es_ES
Patrocinador
dc.description.sponsorship
Fondo Nacional de Desarrollo Cientifico y Tecnologico-Fondecyt
11130007
3140448
1121078
1120286
Millennium Institute on Immunology and Immunotherapy
P09-016-F
UNAB
DI-741-15/N